© 2021 MJH Life Sciences™ and Center for Biosimilars. All rights reserved. https://www.centerforbiosimilars.com/news Center for Biosimilars articles Center for Biosimilars articles en-us Thu, 09 Apr 2026 04:23:37 +0000 5 144 47 https://www.centerforbiosimilars.com/news https://www.centerforbiosimilars.com/Biosimilars_ajmc_logo.png https://www.centerforbiosimilars.com/view/no-efficacy-loss-after-multiple-ustekinumab-biosimilar-switches-in-psoriasis Center for Biosimilars Articles us Thu, 02 Apr 2026 16:36:01 +0000 Center for Biosimilars https://www.centerforbiosimilars.com/rss/no-efficacy-loss-after-multiple-ustekinumab-biosimilar-switches-in-psoriasis https://www.centerforbiosimilars.com/view/fda-approves-teva-biosimilar-for-denosumab-in-osteoporosis Center for Biosimilars Articles us Tue, 31 Mar 2026 14:03:08 +0000 Center for Biosimilars https://www.centerforbiosimilars.com/rss/fda-approves-teva-biosimilar-for-denosumab-in-osteoporosis https://www.centerforbiosimilars.com/view/bone-health-in-oncology-closing-gaps-reducing-costs-and-unlocking-biosimilar-value Center for Biosimilars Articles us Mon, 30 Mar 2026 17:26:51 +0000 Center for Biosimilars https://www.centerforbiosimilars.com/rss/bone-health-in-oncology-closing-gaps-reducing-costs-and-unlocking-biosimilar-value https://www.centerforbiosimilars.com/view/biosimilar-ct-p43-matches-ustekinumab-in-treating-moderate-to-severe-plaque-psoriasis Center for Biosimilars Articles us Fri, 20 Mar 2026 23:15:44 +0000 Center for Biosimilars https://www.centerforbiosimilars.com/rss/biosimilar-ct-p43-matches-ustekinumab-in-treating-moderate-to-severe-plaque-psoriasis https://www.centerforbiosimilars.com/view/golimumab-biosimilar-matches-reference-drug-in-year-long-ra-trial Center for Biosimilars Articles us Thu, 19 Mar 2026 15:15:59 +0000 Center for Biosimilars https://www.centerforbiosimilars.com/rss/golimumab-biosimilar-matches-reference-drug-in-year-long-ra-trial https://www.centerforbiosimilars.com/view/switching-to-biosimilar-etanercept-shows-no-impact-on-efficacy-safety-across-18-trials Center for Biosimilars Articles us Mon, 16 Mar 2026 17:00:29 +0000 Center for Biosimilars https://www.centerforbiosimilars.com/rss/switching-to-biosimilar-etanercept-shows-no-impact-on-efficacy-safety-across-18-trials https://www.centerforbiosimilars.com/view/gaps-in-knowledge-persist-around-biosimilar-insulin-switching-review-finds Center for Biosimilars Articles us Thu, 12 Mar 2026 17:45:29 +0000 Center for Biosimilars https://www.centerforbiosimilars.com/rss/gaps-in-knowledge-persist-around-biosimilar-insulin-switching-review-finds https://www.centerforbiosimilars.com/view/global-biosimilar-market-sees-structural-shifts-regulatory-hurdles-and-pipeline-gains Center for Biosimilars Articles us Tue, 10 Mar 2026 19:37:56 +0000 Center for Biosimilars https://www.centerforbiosimilars.com/rss/global-biosimilar-market-sees-structural-shifts-regulatory-hurdles-and-pipeline-gains https://www.centerforbiosimilars.com/view/fda-issues-draft-guidance-aimed-at-cutting-expenses-for-biosimilar-pk-studies Center for Biosimilars Articles us Mon, 09 Mar 2026 20:30:05 +0000 Center for Biosimilars https://www.centerforbiosimilars.com/rss/fda-issues-draft-guidance-aimed-at-cutting-expenses-for-biosimilar-pk-studies https://www.centerforbiosimilars.com/view/clinician-confidence-in-ophthalmology-biosimilars-remains-low-across-europe Center for Biosimilars Articles us Fri, 06 Mar 2026 19:38:40 +0000 Center for Biosimilars https://www.centerforbiosimilars.com/rss/clinician-confidence-in-ophthalmology-biosimilars-remains-low-across-europe https://www.centerforbiosimilars.com/view/biosimilars-development-roundup-expanding-global-treatment-options-amidst-rising-us-legal-hurdles Center for Biosimilars Articles us Thu, 05 Mar 2026 20:37:12 +0000 Center for Biosimilars https://www.centerforbiosimilars.com/rss/biosimilars-development-roundup-expanding-global-treatment-options-amidst-rising-us-legal-hurdles https://www.centerforbiosimilars.com/view/biosimilar-backed-triplet-regimen-shows-feasibility-in-heavily-pretreated-liver-cancer Center for Biosimilars Articles us Fri, 27 Feb 2026 14:00:00 +0000 Center for Biosimilars https://www.centerforbiosimilars.com/rss/biosimilar-backed-triplet-regimen-shows-feasibility-in-heavily-pretreated-liver-cancer https://www.centerforbiosimilars.com/view/omalizumab-biosimilar-entry-linked-to-expanded-patient-access-reduced-spending Center for Biosimilars Articles us Thu, 26 Feb 2026 14:27:00 +0000 Center for Biosimilars https://www.centerforbiosimilars.com/rss/omalizumab-biosimilar-entry-linked-to-expanded-patient-access-reduced-spending https://www.centerforbiosimilars.com/view/postmenopausal-osteoporosis-clinical-burden-treatment-barriers-and-the-evolving-role-of-denosumab-biosimilars Center for Biosimilars Articles us Wed, 25 Feb 2026 15:44:02 +0000 Center for Biosimilars https://www.centerforbiosimilars.com/rss/postmenopausal-osteoporosis-clinical-burden-treatment-barriers-and-the-evolving-role-of-denosumab-biosimilars https://www.centerforbiosimilars.com/view/cardinal-health-biosimilar-report-56-billion-in-savings-and-the-road-to-market-sustainability Center for Biosimilars Articles us Tue, 24 Feb 2026 14:00:00 +0000 Center for Biosimilars https://www.centerforbiosimilars.com/rss/cardinal-health-biosimilar-report-56-billion-in-savings-and-the-road-to-market-sustainability https://www.centerforbiosimilars.com/view/biosimilar-trastuzumab-emtansine-shows-consistent-pfs-in-her2-positive-breast-cancer Center for Biosimilars Articles us Fri, 20 Feb 2026 14:52:09 +0000 Center for Biosimilars https://www.centerforbiosimilars.com/rss/biosimilar-trastuzumab-emtansine-shows-consistent-pfs-in-her2-positive-breast-cancer https://www.centerforbiosimilars.com/view/fda-approves-filkri-accord-biopharma-s-short-acting-filgrastim-biosimilar-for-neutropenia Center for Biosimilars Articles us Wed, 18 Feb 2026 19:25:00 +0000 Center for Biosimilars https://www.centerforbiosimilars.com/rss/fda-approves-filkri-accord-biopharma-s-short-acting-filgrastim-biosimilar-for-neutropenia https://www.centerforbiosimilars.com/view/danish-registry-analysis-finds-consistent-safety-after-switching-to-infliximab-biosimilar-gp1111 Center for Biosimilars Articles us Tue, 03 Feb 2026 14:00:00 +0000 Center for Biosimilars https://www.centerforbiosimilars.com/rss/danish-registry-analysis-finds-consistent-safety-after-switching-to-infliximab-biosimilar-gp1111 https://www.centerforbiosimilars.com/view/q-a-with-dr-chelsee-jensen-fda-policy-shifts-biosimilar-development-hurdles-and-market-access-in-2026 Center for Biosimilars Articles us Mon, 02 Feb 2026 17:45:00 +0000 Center for Biosimilars https://www.centerforbiosimilars.com/rss/q-a-with-dr-chelsee-jensen-fda-policy-shifts-biosimilar-development-hurdles-and-market-access-in-2026 https://www.centerforbiosimilars.com/view/early-evidence-supports-km118-as-a-biosimilar-to-reference-pertuzumab Center for Biosimilars Articles us Wed, 28 Jan 2026 22:00:20 +0000 Center for Biosimilars https://www.centerforbiosimilars.com/rss/early-evidence-supports-km118-as-a-biosimilar-to-reference-pertuzumab https://www.centerforbiosimilars.com/view/milestone-approvals-evolving-pbm-models-may-redefine-2026-biosimilar-landscape Center for Biosimilars Articles us Tue, 27 Jan 2026 16:32:46 +0000 Center for Biosimilars https://www.centerforbiosimilars.com/rss/milestone-approvals-evolving-pbm-models-may-redefine-2026-biosimilar-landscape https://www.centerforbiosimilars.com/view/fda-draft-guidance-on-biosimilars-is-a-win-for-patients-now-congress-must-finish-the-job Center for Biosimilars Articles us Mon, 26 Jan 2026 22:07:22 +0000 Center for Biosimilars https://www.centerforbiosimilars.com/rss/fda-draft-guidance-on-biosimilars-is-a-win-for-patients-now-congress-must-finish-the-job https://www.centerforbiosimilars.com/view/biosimilar-competition-linked-to-lower-out-of-pocket-costs-for-medicare-patients Center for Biosimilars Articles us Wed, 21 Jan 2026 19:54:04 +0000 Center for Biosimilars https://www.centerforbiosimilars.com/rss/biosimilar-competition-linked-to-lower-out-of-pocket-costs-for-medicare-patients https://www.centerforbiosimilars.com/view/perceptions-still-play-a-central-role-in-biosimilar-insulin-switching Center for Biosimilars Articles us Tue, 20 Jan 2026 22:01:09 +0000 Center for Biosimilars https://www.centerforbiosimilars.com/rss/perceptions-still-play-a-central-role-in-biosimilar-insulin-switching https://www.centerforbiosimilars.com/view/trial-data-support-equivalence-of-denosumab-biosimilar-in-postmenopausal-osteoporosis Center for Biosimilars Articles us Fri, 16 Jan 2026 13:37:46 +0000 Center for Biosimilars https://www.centerforbiosimilars.com/rss/trial-data-support-equivalence-of-denosumab-biosimilar-in-postmenopausal-osteoporosis https://www.centerforbiosimilars.com/view/what-australia-s-experience-reveals-about-biosimilar-adoption-and-pricing Center for Biosimilars Articles us Thu, 15 Jan 2026 19:07:39 +0000 Center for Biosimilars https://www.centerforbiosimilars.com/rss/what-australia-s-experience-reveals-about-biosimilar-adoption-and-pricing https://www.centerforbiosimilars.com/view/eye-on-pharma-global-approvals-launches-and-strategic-partnerships Center for Biosimilars Articles us Mon, 12 Jan 2026 19:25:24 +0000 Center for Biosimilars https://www.centerforbiosimilars.com/rss/eye-on-pharma-global-approvals-launches-and-strategic-partnerships https://www.centerforbiosimilars.com/view/real-world-study-finds-stable-vision-after-switch-to-ranibizumab-biosimilar Center for Biosimilars Articles us Wed, 07 Jan 2026 17:26:26 +0000 Center for Biosimilars https://www.centerforbiosimilars.com/rss/real-world-study-finds-stable-vision-after-switch-to-ranibizumab-biosimilar https://www.centerforbiosimilars.com/view/evidence-supports-safe-effective-switching-to-etanercept-biosimilars Center for Biosimilars Articles us Tue, 06 Jan 2026 19:33:57 +0000 Center for Biosimilars https://www.centerforbiosimilars.com/rss/evidence-supports-safe-effective-switching-to-etanercept-biosimilars https://www.centerforbiosimilars.com/view/fda-approves-amneal-denosumab-biosimilars-capping-year-of-market-expansion Center for Biosimilars Articles us Tue, 06 Jan 2026 12:00:00 +0000 Center for Biosimilars https://www.centerforbiosimilars.com/rss/fda-approves-amneal-denosumab-biosimilars-capping-year-of-market-expansion